ArticleAmerican journal of hematology2024

Safety and efficacy of a new high-dose regimen of panobinostat, gemcitabine, busulfan, and melphalan for 1st or 2nd salvage ASCT for refractory/relapsed or high-risk myeloma: Matched-pair comparisons with concurrent control cohorts.

Yago Nieto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.